Genkyotex announces the closing of the acquisition by Calliditas Therapeutics of a controlling interest in Genkyotex

Genkyotex announces the closing of the acquisition by Calliditas Therapeutics of a controlling interest in Genkyotex

Genkyotex (Euronext Paris & Brussels: FR0013399474 –GKTX), a biopharmaceutical company and the leader in NOX therapies, announced the closing of the acquisition by Calliditas Therapeutics AB (“Calliditas”; Nasdaq OMX –CALTX; NASDAQ -CALT) of 62.7% of Genkyotex in an off-market transaction.

For more information, https://www.genkyotex.com/images/PDF/GB/1_Press_Releases/2020/2020.11.03_PR_GKTX_Block_Trade_with_Calliditas_EN_d7c28.pdf